Trovagene

TROV NASDAQ
2.110
-0.030
-1.40%
已收盘, 16:00 07/19 EDT
开盘
2.170
昨收
2.140
最高
2.170
最低
2.090
成交量
3.33万
成交均量(3M)
24.10万
52周最高
9.65
52周最低
2.080
换手率
0.64%
市值
1,102.45万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Trovagene TROV股票价格,Trovagene股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers. PCM-075 developed high selectivity to PLK1, to be administered orally, and to have a relatively short drug half-life of approximately 24 hours compared to other PLK inhibitors. PCM-075 has completed a safety study in patients with advanced metastatic solid tumors with a phase Ib/II clinical trial in patients with AML underway.
展开 >

最近浏览

名称
价格
涨跌幅